Pseudocirrhosis in Patients with Metastatic Breast Cancer after Treatment with Eribulin

Nadiye Akdeniz, Muhammet Ali Kaplan, Mehmet Küçüköner, Zuhat Urakçı, OÄŸur Karhan and Abdurrahman IşıkdoÄŸan

Department of Medical Oncology, Dicle University, Diyarbakır, Turkey

^*Correspondance to: Muhammet Ali Kaplan 

 PDF  Full Text Case Report | Open Access

Abstract:

Pseudocirrhosis, an important complication of metastatic disease, is rarely seen and most commonly described in patients with breast cancer. Despite its radiological and clinical similarity with cirrhosis, it is different pathophysiologically. Eribulin, a novel synthetic chemotherapeutic agent, is one of the few choices of treatments that prolong overall survival in metastatic breast cancer who previously treated with multiple chemotherapy regimens. Herein we report two patients with breast cancer and liver metastasis who developed pseudocirrhosis after achieving a clinical and radiographic response to eribulin.

Keywords:

Breast cancer; Pseudocirrhosis; Eribulin

Cite the Article:

Akdeniz N, Ali Kaplan M, Küçüköner M, Urakçı Z, Karhan O, Işıkdoğan A. Pseudocirrhosis in Patients with Metastatic Breast Cancer after Treatment with Eribulin. World J Surg Surgical Res. 2018; 1: 1057.